What AbbVie's Recent Drug News Means for Shareholders

What AbbVie's Recent Drug News Means for Shareholders

Source: 
Motley Fool
snippet: 
  • Skyrizi was demonstrated to be quite effective in treating Crohn's disease patients in phase 3 clinical trials.
  • If approved, Skyrizi would gain access to hundreds of thousands of patients in the EU.
  • AbbVie's valuation and yield are attractive for value and income investors alike.